- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| IMMUNOVIA Aktie jetzt für 0€ handeln | |||||
| Mo | Immunovia AB announces outcome of exercise of warrants series TO 2 | 234 | PR Newswire | LUND, Sweden, Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January... ► Artikel lesen | |
| 08.01. | Immunovia AB (Publ) presents Nomination Committee | 165 | PR Newswire | LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee.... ► Artikel lesen | |
| 02.01. | The exercise period for warrants of series TO 2 beings today: Immunovia AB | 255 | PR Newswire | LUND, Sweden, Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2... ► Artikel lesen | |
| 02.01. | IMMUNOVIA AB: The exercise period for warrants of series TO 2 beings today | 2 | Cision News | ||
| 28.12.24 | Immunovia AB: Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme | 610 | PR Newswire | LUND, Sweden, Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been... ► Artikel lesen | |
| 20.12.24 | IMMUNOVIA AB: Immunovia discovery study published in top protein research journal | 8 | Cision News | ||
| 19.12.24 | Immunovia AB: End of the Year 2024 Letter from Immunovia CEO Jeff Borcherding | 113 | PR Newswire | LUND, Sweden, Dec. 19, 2024 /PRNewswire/ -- As we near the holidays and year end, I am energized by what Immunovia has accomplished in 2024 and the opportunities... ► Artikel lesen | |
| 18.12.24 | IMMUNOVIA AB: Immunovia CEO and board members announce intention to fully exercise their TO2 warrants | 1 | Cision News | ||
| 16.12.24 | IMMUNOVIA AB: Immunovia to host a webcast with the opportunity to learn more about the positive clinical validation of its next-generation pancreatic cancer test | 1 | Cision News | ||
| 11.12.24 | IMMUNOVIA AB: Immunovia announces financial calendar for financial year 2025/2026 | 3 | Cision News | ||
| 09.12.24 | Immunovia AB: Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer | 93 | PR Newswire | LUND, Sweden, Dec. 9, 2024 /PRNewswire/ -- Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, today announces the successful completion of the... ► Artikel lesen | |
| 28.11.24 | IMMUNOVIA AB: Immunovia to present at the Redeye Technology & Life Science Day | 2 | Cision News | ||
| 27.11.24 | Immunovia AB: Immunovia Publishes Interim Report for January-September 2024 | 244 | PR Newswire | LUND, Sweden, Nov. 27, 2024 /PRNewswire/ --
July-September 2024
Net sales, which for the quarter only included royalties, amounted to 235 KSEK (488).Net earnings amounted to -51.1... ► Artikel lesen | |
| 15.11.24 | IMMUNOVIA AB: Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas-Inherited Gastrointestinal Cancers | 3 | Cision News | ||
| 12.11.24 | Immunovia AB: Invitation to Immunovia's Q3 presentation | 176 | PR Newswire | LUND, Sweden, Nov. 12, 2024 /PRNewswire/ -- Immunovia will publish its third quarter 2024 results on November 27, 2024 at 8:30 am CET. Analysts, investors and media are invited to a webcast... ► Artikel lesen | |
| 07.11.24 | Immunovia AB: Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium | 270 | PR Newswire | SAN DIEGO, Nov. 7, 2024 /PRNewswire/ -- Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual... ► Artikel lesen | |
| 07.10.24 | Immunovia AB: Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer | 377 | PR Newswire | LUND, Sweden, Oct. 7, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples... ► Artikel lesen | |
| 02.10.24 | Immunovia AB: Immunovia completes analytical validation of its next-generation pancreatic cancer test | 300 | PR Newswire | LUND, Sweden, Oct. 2, 2024 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has completed the analytical validation... ► Artikel lesen | |
| 30.09.24 | Change in number of shares and votes in Immunovia AB (publ) | 228 | PR Newswire | LUND, Sweden, Sept. 30, 2024 /PRNewswire/ -- During September 2024, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due to the rights issue of... ► Artikel lesen | |
| 27.09.24 | Nasdaq Stockholm AB: New equity right for trading, Immunovia AB (publ) | 296 | GlobeNewswire | At the request of Immunovia AB (publ), Immunovia AB equity rights TO 2 and TO 3
will be traded on Nasdaq Stockholm as from September 30, 2024.
IMMNOV TO 2
Security name: Immunovia AB TO 2
---------------------------------
Short... ► Artikel lesen |
Seite:
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 9,700 | -0,30 % | Amazon Adds Teladoc Health to Health Benefits Program | ||
| BECTON DICKINSON | 231,00 | +0,09 % | BD And Biosero Partner To Integrate Robotics With Flow Cytometry | WASHINGTON (dpa-AFX) - BD. (BDX), a global medical technology company, and Biosero, a developer of laboratory automation solutions, Thursday announced that they have entered into a framework... ► Artikel lesen | |
| HIMS & HERS HEALTH | 29,510 | -0,51 % | Hims & Hers Health: Rechtsvorstand verkauft Aktien im Wert von über 1,6 Millionen US-Dollar | ||
| DEXCOM | 84,13 | -0,05 % | Dexcom CEO says 2025 is 'shaping up to be a good year' with Stelo launch, GenAI integration | ||
| INVITAE | 0,110 | 0,00 % | Invitae Aktie: Drastischer Kursverfall trotz Umsatzwachstum | Der Aktienkurs des Biotechnologieunternehmens Invitae ist in den letzten Tagen stark eingebrochen. Am 8. September fiel der Kurs um 25% auf 0,0003 USD, was einen besorgniserregenden Trend fortsetzt.... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,906 | 0,00 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025 | SEATTLE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 | - Improved loss from operations by 31% -
- Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,520 | 0,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Successfully Transitions First Products to New EU MDR Requirements for Class IIb Medical Devices | BOULDER, CO / ACCESSWIRE / December 5, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous... ► Artikel lesen | |
| RYMAN HEALTHCARE | 2,320 | -0,60 % | Short Interest in Ryman Healthcare Limited (OTCMKTS:RYHTY) Drops By 28.6% | ||
| CYTOSORBENTS | 0,960 | -2,93 % | CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue | Fourth quarter product revenue growth estimated at 22% to 25% year-over-year Fourth quarter gross margin estimated to improve to approximately 70% Management will host in-person investor... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,954 | +8,10 % | Tempest Therapeutics: Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC) | BRISBANE, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics... ► Artikel lesen | |
| ONTRAK | 1,730 | -2,26 % | Ontrak Inc. (OTRK): AI-Powered Healthcare Solutions Under $2 Billion | ||
| STAAR SURGICAL | 23,740 | +3,26 % | STAAR Surgical Company: STAAR Surgical and Lucy Bronze, MBE See Eye to Eye on Vision Correction | Women's football star benefits on and off the pitch from EVO ICL vision correction procedure
LONDON, Nov. 4, 2024 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer... ► Artikel lesen | |
| SENSEONICS | 1,050 | +8,83 % | Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special Meeting | GERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable... ► Artikel lesen | |
| PATTERSON COMPANIES | 29,600 | -0,67 % | Patterson Companies Announces Expiration of "Go-Shop" Period | ST. PAUL, Minn.--(BUSINESS WIRE)--Patterson Companies, Inc. (Nasdaq: PDCO), a leading dental and animal health distributor, today announced the expiration of the 40-day "go-shop" period under the... ► Artikel lesen |
Das Unternehmen IMMUNOVIA AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,000 (+1,99 %) liegt der Kurs bei 0,021 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNOVIA AB finden Sie auf Wallstreet Online.
